Logo
T

Tubulis GmbH

60 employees

TubulisĀ® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

Investor insights

Funding rounds participated in

$139M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Funding rounds raised

Total raised

$139M

from 3 investors over 1 rounds

T

Tubulis GmbH raised $139M on April 14, 2024

Investors: EQT Life Sciences, Nextech Invest and + 11 Other investors

FAQ